Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798730 | 0.82 | NR3C1 (0.46) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL22875390 | 0.81 | NR3C1 (0.45) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL22518626 | 0.80 | NR3C1 (0.44) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL22122128 | 0.79 | GPR119 (0.50) | NR3C1GPR119HPGDPTPN2PTPN1 | |
| SCHEMBL22122133 | 0.78 | GPR119 (0.46) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL23546345 | 0.76 | GPR119 (0.42) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL23546412 | 0.76 | GPR119 (0.43) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL2800381 | 0.75 | USP30 (0.44) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL23546418 | 0.75 | GPR119 (0.42) | NR3C1GPR119KDM4EMAPTTHRB | |
| SCHEMBL22518604 | 0.74 | NR3C1 (0.44) | NR3C1GPR119KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-3898615-A1 | 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER | Array Biopharma, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113474337-A | 7- ((3, 5-dimethoxyphenyl) amino) quinoxaline derivatives as FGFR inhibitors for the treatment of cancer | 奥瑞生物药品公司 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020131674-A1 | 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER | ARRAY BIOPHARMA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020131674-A1 | 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER | ARRAY BIOPHARMA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | NR3C1 1971/4885GPR119 2855/4885KDM4E 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.